GSK Taps Miels as CEO With Walmsley Stepping Down

Watch GSK Taps Miels as CEO With Walmsley Stepping Down - Bloomberg on Dailymotion

Transcript

00:00Shares of GSK getting a boost on some C-suite shake-up news.

00:03CEO Emma Walmsley is stepping down after almost nine years at the helm.

00:08She'll be succeeded by the current chief commercial officer, Luke Mills.

00:13Joining us for more now is Bloomberg Health reporter Ashley Frallong.

00:16Ashley, shares in GSK have declined under Walmsley, but you see that.

00:21I mean, that's not necessarily a report card maybe on her reputation throughout her tenure.

00:29But how will her tenure be seen? What challenges face her successor?

00:35She's had a lot of wins as well as some challenges, as many pharma CEOs have over the past couple of years.

00:42I think core among what Emma has tried to do is really to invest in the pipeline.

00:46She's really put a lot of money into the pipeline of drugs that are coming to market.

00:51She also fended off an activist investor, Elliot.

00:54She resolved litigation in the U.S. around Zantac.

00:57But still, investors are questioning whether the pipeline is sufficient,

01:02whether the pipeline can actually meet her ambition to get to $40 billion in sales by 2031.

01:09So that's really going to be what Luke Miles really needs to do, is to get to that goal.

01:15And that's going to be about the pipeline and about delivering the current drugs that are on the market

01:18and actually selling them to more people.